Dr. Reddy's Laboratories Completes USFDA Pre-Approval and GMP Inspection at Srikakulam Unit
Dr. Reddy's Laboratories Limited has completed a crucial Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection by the United States Food & Drug Administration (USFDA). The audit was conducted at the FTO-SEZ Process Unit-02 located in Srikakulam, Andhra Pradesh.The comprehensive inspection took place over ten days, spanning from July 20, 2026, to July 29, 2026.
Following the conclusion of the review, Dr. Reddy's Laboratories reported that a Form 483 was issued regarding the site. The company noted that there were three observations detailed in the document.
Dr. Reddy's Laboratories has indicated that it plans to address the identified observations within the stipulated timeline set forth by the USFDA.
DRREDDY Stock Price Movement
On Wednesday, shares of Dr. Reddy's Laboratories Limited closed higher in the market, gaining 0.65% as the stock settled at ₹1142.30. The equity traded on a volume totaling 1.28 million shares during the previous session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.